Floatz logo

rg1507

Non-Small Cell Lung Carcinoma

Hoffmann-La RochePhase 2Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
59/ 100

Competitive context

1206 Active assets in the Non-Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Veliparib
AbbVie
Phase 3BBB

View all 50 →

Same molecule, other indications

rg1507 is also rated in:

breast cancerDormant
CC
Indicative ·
41 / 100
View asset →
neoplasmDormant
C
Indicative ·
35 / 100
View asset →
prostate cancerDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →